Study #2021-0718
A Phase I Multi-Dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (Cynk-001) with or without Recombinant Human Interleukin-2 (rhIL-2) In Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete
MD Anderson Study Status
Not Accepting
Treatment Agent
CYNK-001
Description
This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy. The safety of this treatment will be evaluated, and researchers want to learn if NK cells will help in treating acute myeloid leukemia.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type, Neoplasms, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Alkylating Agents, Antimetabolites, Antineoplastic, Antiviral Agents, Analgesics, Non-narcotic, Anti-infective Agents, Analgesics, Peripheral Nervous System Agents, Hematologic Diseases, Hematologic Neoplasms, Leukemia in Remission, Relapsed Adult AML, Refractory AML
Study phase:
Phase I
Physician name:
Naveen Pemmaraju
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.